Triptolide Mitigates Radiation-Induced Pulmonary Fibrosis

Area of Science:

• Radiation Oncology
• Pulmonary Medicine
• Pharmacology

Background:

• Radiation therapy can cause late pulmonary side effects, including fibrosis.
• Triptolide (TPL) is known to inhibit pro-inflammatory cytokines, suggesting a potential role in mitigating radiation damage.
• Understanding the efficacy of TPL in preventing radiation-induced pulmonary fibrosis is crucial for patient care.

Purpose of the Study:

• To evaluate the effect of Triptolide (TPL) in mitigating radiation-induced late pulmonary side effects.
• To assess TPL's impact on pulmonary function, density, and fibrosis markers in a mouse model.
• To investigate the correlation between TPL treatment and the reduction of specific pro-inflammatory cytokines.

Main Methods:

• C57BL/6 mice were exposed to radiation (15 Gy) and treated with TPL (0.25 mg/kg i.v.) or vehicle.
• Enzyme-linked immunosorbent assays were used to measure cytokine levels in cell cultures and lung lysates.
• Pulmonary function (respiratory rate, compliance), density, hydroxyproline levels, and histopathology were assessed at 5 months post-irradiation.

Main Results:

• TPL treatment significantly improved respiratory rate and pulmonary compliance compared to vehicle control.
• Radiation with TPL showed a 41% reduction in pulmonary density and a 25% reduction in lung hydroxyproline.
• TPL significantly reduced seventeen cytokines, including IL-1β, TGF-β1, and IL-13, and decreased fibrotic foci in lung tissue.

Conclusions:

• Triptolide (TPL) demonstrates significant potential in mitigating radiation-induced pulmonary fibrosis.
• TPL's anti-inflammatory and anti-fibrotic effects contribute to improved pulmonary function and reduced lung damage.
• TPL may serve as a novel therapeutic agent for preventing or treating radiation-induced pulmonary complications.